Recent Advancement in the Synthesis of Ir-Based Complexes

[Image: see text] Cancer is a devastating disease with over 100 types, including lung and breast cancer. Cisplatin and metal-based drugs are limited due to their drug resistance and side effects. Iridium-based compounds have emerged as promising candidates due to their unique chemical properties and resemblance to platinum compounds. The objective of this study is to investigate the synthesis and categorization of iridium complexes, with a particular emphasis on their potential use as anticancer agents. The major focus of this research is to examine the synthesis of these complexes and their relevance to the field of cancer treatment. The negligible side effects and flexibility of cyclometalated iridium(III) complexes have garnered significant interest. Organometallic half-sandwich Ir(III) complexes have notable benefits in cancer research and treatment. The review places significant emphasis on categorizing iridium complexes according to their ligand environment, afterward considering the ligand density and coordination number. This study primarily focuses on several methods for synthesizing cyclometalated and half-sandwich Ir complexes, divided into subgroups based on ligand denticity. The coordination number of iridium complexes determines the number of ligands coordinated to the central iridium atom, which impacts their stability and reactivity. Understanding these complexes is crucial for designing compounds with desired properties and investigating their potential as anticancer agents. Cyclometalated iridium(III) complexes, which contain a meta-cycle with the E-M-C order σ bond, were synthesized in 1999. These complexes have high quantum yields, significant stock shifts, luminescence qualities, cell permeability, and strong photostability. They have been promising in biosensing, bioimaging, and phosphorescence of heavy metal complexes.